Cuorips
4894.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥243m | ¥258m | ¥23m | ¥38m | ¥14m | ¥220,000 |
| Operating income | −¥819m | −¥472m | −¥587m | −¥450m | −¥373m | — |
| Ordinary income | −¥770m | −¥501m | −¥626m | −¥450m | −¥373m | −¥296m |
| Total assets | ¥5.5bn | ¥5.8bn | ¥6.2bn | ¥3.6bn | ¥4.0bn | ¥4.4bn |
| Net assets / equity | ¥5.1bn | ¥5.6bn | ¥6.0bn | ¥3.5bn | ¥3.9bn | ¥4.2bn |
| Operating cash flow | — | — | — | −¥402m | −¥221m | −¥283m |
| EPS (basic) | ¥-93.92 | ¥-63.05 | ¥-85.6 | ¥-79.9 | ¥-66.6 | ¥-123.65 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 9
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 164 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 154 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 43 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 120 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 19 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 44 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 29 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 97 figures · EDINET |